Psilocybin-Assisted Therapy in Treatment-Resistant Depression

This Phase III interventional trial (n=20), conducted by the University of North Carolina, Chapel Hill, aims to assess the efficacy and safety of Psilocybin-Assisted Therapy (PAT, 25mg, 2x) in adults with treatment-resistant depression (TRD).

The study will compare the outcomes of participants who receive one treatment session of psilocybin-assisted therapy with those who receive two treatment sessions spaced two weeks apart. A total of 20 participants are estimated to be enrolled, with ages ranging from 18 to 70 years.

Participants meeting eligibility criteria, including a DSM-V diagnosis of major depressive disorder and failure to respond to at least two guideline-concordant pharmacological treatments, will undergo one or two treatment sessions involving the administration of 25mg of psilocybin.

The primary outcome measures include changes in depression severity assessed by the Hamilton Depression Rating Scale (HAM-D-17) and the Quick Inventory of Depressive Symptomatology Short Response-16 (QIDS SR-16) scores at various time points up to 12 months after treatment.

Secondary outcome measures include the number of participants achieving remission and response at different time points, as well as the time to relapse in those who initially responded to treatment.

This trial is designed as a randomized, parallel assignment study, with single masking of outcomes assessors. The study will provide valuable insights into the effectiveness of psilocybin-assisted therapy as a potential treatment for TRD. Recruitment for this trial began in April 2024, and the estimated primary completion date is September 2025, with a study completion date estimated for September 2026.

Topic Treatment-Resistant Depression Depression Safety
Compound Psilocybin
Country United States of America
Visit trial
Status Recruiting
Results Published No
Start date 19 April 2024
End date 30 September 2026
Phase Phase III
Design Blinded
Type Interventional
Generation First
Participants 20
Sex All
Age 18- 70
Therapy Yes

Trial Details

This clinical trial seeks to evaluate the efficacy of psilocybin-assisted therapy in treating depression by investigating its impact on symptom alleviation and the duration of therapeutic effects. Participants will undergo screening and preparation sessions before receiving psilocybin in one or two treatment sessions, followed by a series of follow-up sessions over the course of a year. Through surveys and assessments, researchers aim to determine changes in symptoms and participant experiences, while also comparing the effectiveness of one versus two treatment sessions in improving depressive symptoms.

Trial Number NCT06303739

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.